Select Language
Mucin-1
Mucin-1 Overview
| English Name | Mucin-1 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 28 | Target Synonym | PEM，Medullary Cystic Kidney Disease 1 (Autosomal Dominant)，Tumor Associated Epithelial Mucin，CD227 Antigen，H23 Antigen，MUC-1/SEC，ADMCKD1，Cancer antigen 15-3，Tumor-associated mucin，MUC1-alpha，MUC1-beta，MUC-1/X，MUC1/ZD，Mucin-1，ADMCKD，MCKD1，MAM6，MCKD，MCD，Polymorphic epithelial mucin，PUM，MUC1-NT，Episialin，CD227，MUC1-CT，MUC1，Mucin 1， Cell Surface Associated，Tumor-Associated Epithelial Membrane Antigen，Peanut-Reactive Urinary Mucin，Carcinoma-Associated Mucin，Krebs Von Den Lungen-6，CA 15-3，H23AG，MUC-1，KL-6，PEMT，EMA，Breast carcinoma-associated antigen DF3，Mucin 1， Transmembrane |
| Highest Development Stage | Phase 2 Clinical | ||
| English Name | Mucin-1 |
| Target Synonym | PEM，Medullary Cystic Kidney Disease 1 (Autosomal Dominant)，Tumor Associated Epithelial Mucin，CD227 Antigen，H23 Antigen，MUC-1/SEC，ADMCKD1，Cancer antigen 15-3，Tumor-associated mucin，MUC1-alpha，MUC1-beta，MUC-1/X，MUC1/ZD，Mucin-1，ADMCKD，MCKD1，MAM6，MCKD，MCD，Polymorphic epithelial mucin，PUM，MUC1-NT，Episialin，CD227，MUC1-CT，MUC1，Mucin 1， Cell Surface Associated，Tumor-Associated Epithelial Membrane Antigen，Peanut-Reactive Urinary Mucin，Carcinoma-Associated Mucin，Krebs Von Den Lungen-6，CA 15-3，H23AG，MUC-1，KL-6，PEMT，EMA，Breast carcinoma-associated antigen DF3，Mucin 1， Transmembrane |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 28 |
| Highest Development Stage | Phase 2 Clinical |
Mucin-1 Product List
- Product Category
Protein (19)Antibody (1)Kits (1)
- Product Status
Launched (21)
- Species
Human (13)Cynomolgus (5)Mouse (3)
- Tag
Fc Tag (7)Llama IgG Fc Tag (1)His Tag (6)His Tag & Avi Tag (3)Mouse IgG Fc Tag (2)- (2)
- Conjugate
Unconjugated (16)Biotin-labeled (3)APC Labeled (1)- (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT MU1-H52H5 |  Human | HEK293 | Human Mucin-1 / MUC-1 (1036-1155) Protein, His Tag |  |  |  |
HOT MU1-H52H9 | Human | HEK293 | Human Mucin-1 / MUC-1 (890-1158) Protein, His Tag, low endotoxin (MALS verified) |  | | |
HOT MU1-H82E5 | Human | HEK293 | Biotinylated Human Mucin-1 (890-1158) Protein, His,Avitag™ (MALS verified) |  | |  |
CEA-B055 | Human | - | Human MUCIN 1/MUC1 ELISA Kit | |||
MU1-H5153 | Human | E. coli | Human Mucin-1 / MUC-1 (116-173) Protein, Fc Tag |  | | |
MU1-H5252 | Human | HEK293 | Human Mucin-1 / MUC-1 Protein, Fc Tag, low endotoxin |  | | |
MU1-H5254 | Human | HEK293 | Human Mucin-1 / MUC-1 (24-380) Protein, Fc Tag |  | | |
MU1-H5255 | Human | HEK293 | Human Mucin-1 / MUC-1 Protein, Llama IgG2b Fc Tag, low endotoxin |  | | |
MU1-H5256 | Human | HEK293 | Human Mucin-1 / MUC-1 (116-173) Protein, Fc Tag |  | | |
MU1-H5258 | Human | HEK293 | Human Mucin-1 / MUC-1 (890-1158) Protein, Fc Tag (MALS verified) |  | | |
Total: 21
- 1
- 2
- 3
Mucin-1 Background
Membrane mucins have several functions in epithelial cells including cytoprotection, extravasation during metastases, maintenance of luminal structure, and signal transduction. MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites. Interacts via its C-terminus with PDZK1 and this interaction appears important for proper localization. Probably plays a role in maintaining homeostasis on mucosal surfaces.
Mucin-1 Synonyms
Mucin 1,MUC1,CD227,EMA,H23AG,KL-6,MAM6,MUC-1,SEC,MUC-1,X,MUC1,ZD,PEM,PEMT,PUM,CA15-3,Episialin
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) | CVAC-301; CV-301 | Phase 2 Clinical | Therion Biologics | Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Melanoma; Neoplasm Metastasis; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Urinary Bladder Neoplasms | Details |
| PD-1 Knockout Anti-MUC1 CAR-T Cells (Guangzhou Anjie Biomedical) | AJMUC1 | Phase 2 Clinical | Guangzhou Anjie Biomedical Technology | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lung Neoplasms; Prostatic Neoplasms | Details |
| Anti-MUC1 monoclonal antibody (OncoQuest) | AR20.5; mAb-AR20.5; Anti-MUC1 AR20.5 | Phase 2 Clinical | Altarex | Pancreatic Neoplasms | Details |
| GO-2032c | GO-203-2C | Phase 2 Clinical | Dana-Farber Cancer Institute, Genus Oncology Llc | Leukemia, Myeloid, Acute; Multiple Myeloma; Solid tumours | Details |
| MUC1-Poly-ICLC | MUC1-poly-ICLC | Phase 2 Clinical | University Of Pittsburgh | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma | Details |
| EB-DT-CAR-NK | EB-DT-CAR-NK | Phase 2 Clinical | Beijing Biotech | Breast Neoplasms; Triple Negative Breast Neoplasms | Details |
| EB-DNK102 | EB-DNK102 | Phase 2 Clinical | Beijing Biotech | Carcinoma, Pancreatic Ductal | Details |
| EB-DNK101 | EB-DNK101 | Phase 2 Clinical | Beijing Biotech | Carcinoma, Pancreatic Ductal | Details |
| DS-3939 | DS-3939; DS-3939a; GT-00A | Phase 2 Clinical | Daiichi Sankyo Inc | Solid tumours | Details |
| BM7PE | Phase 2 Clinical | Oslo University Hospital | Colorectal Neoplasms | Details | |
| Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney) | Phase 2 Clinical | Guangzhou Anjie Biomedical Technology, The First Affiliated Hospital Of Guangdong Pharmaceutical University, University of Sydney | Carcinoma, Non-Small-Cell Lung | Details | |
| huMNC2-CAR44 | huMNC2-CAR44 | Phase 1 Clinical | Minerva Biotechnologies Co | Metastatic breast cancer | Details |
| ICTCAR-052 | ICTCAR-052 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Breast Neoplasms; Lung Neoplasms; Pancreatic Neoplasms | Details |
| recombinant adenovirus vector vaccine targeting MUC1 (MicroVax) | Phase 1 Clinical | Microvax Llc | Neoplasms | Details | |
| P-MUC1C-ALLO1 | P-MUC1C-ALLO1; P-MUC1C-101 | Phase 1 Clinical | Poseida Therapeutics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Nasopharyngeal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| NEOK-002 | ABL209; ABL-209; NEOK002; NEOK-002 | Phase 1 Clinical | Abl Bio Inc, Biocytogen Pharmaceuticals (Beijing) Co Ltd | Neoplasms; Solid tumours | Details |
| M-0324 | M-0324; M0324 | Phase 1 Clinical | Merck KGaA, Darmstadt, Germany | Neoplasms; Solid tumours | Details |
| YB-01(Yuanben (Zhuhai Hengqin) Biotech) | YB01; YB-01 | Phase 1 Clinical | Yuanben (Zhuhai Hengqin) Biotechnology Co Ltd | Arthritis, Rheumatoid; Solid tumours | Details |
| SBO-154 | SBO-154 | Phase 1 Clinical | Sun Pharmaceutical Advanced Research Co Ltd | Breast Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| ICTCAR-053 | ICTCAR-053 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms | Details |
| BGB-B3227 | BGB-B3227 | Phase 1 Clinical | BeOne Medicines (Beijing) Co Ltd | Gastrointestinal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| MUC1-peptide-DC-CTL (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Stomach Neoplasms | Details | |
| MUC1-gene-DC-CTL (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Stomach Neoplasms | Details | |
| DM-002 | DM-002; DM002 (Danma) | Phase 1 Clinical | Danma (Suzhou) Biomedical Technology Co Ltd | Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Solid tumours | Details |
| Recombinant HSP-MUC1 fusion protein (Newsummit) | Phase 1 Clinical | Shanghai Xinshengyuan Biological Medicine Co Ltd | Breast Neoplasms | Details | |
| DXC-005 | DXC-005 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| M-1231 | M-1231 | Phase 1 Clinical | Emd Serono Research & Development Institute Inc, Merck Serono | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Solid tumours | Details |
| ICTCAR-046 | ICTCAR-046 | Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms | Details |
- Overview
- Product List
- Clinical Drug Information
Share to: